From VFC's News, Notes & Weekly Stock Watch at VFC's NEW Stock House.
TTNP: Titan Pharmaceuticals closed last week on a high note, trading up by a dime on Friday to finish the day at $1.58. TTNP had slid back to a lows in the $1.30s, after realizing a January run to over $1.80.
With an update or trial results for the latest Phase III Probuphine confirmatory trial due at any time, and add ot that the speculation of a Titan being involved in a merger or acquisition deal, any positive move in the TTNP share price will attract more eyes than usual.
It's not expected that Titan will report earnings until the latter part of the month, and we already know where the Fanapt numbers fell for the previous quarter, so Friday's move is either indicative of nothing, or maybe there's positive news pending for the current week.
Could be regarding Probuphine.
Regardless, Titan is still one to watch.
Disclosure: Long TTNP.